Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma

Analysis of Lung Dose Using Volumetric Analysis in Patients Treated With Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02489838

Enrollment

Registered

2015-07-03

Start date

2012-02-03

Completion date

2019-08-07

Last updated

2020-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Neoplasms

Keywords

Liver Neoplasma, Lung Radiation dose

Brief summary

To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.

Detailed description

To calculate the delivered lung dose using quantitative volumetric analysis in a cohort of patients with unresectable hepatocellular carcinoma who undergo selective internal radiation therapy (SIRT) with Yttrium-90 glass microspheres (TheraSphere®)-and compare this analysis to the lung dose estimated by established criteria. In addition, this study, will summarize the pre and post-treatment clinical data to describe the URMC Y-90 experience.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed therapy * Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or other metastatic diseases to be treated with SIRT (Y-90) * surgical resection not feasible at time of initiation of pre-treatment workup -\> 6 months projected life span * ECOG 0-2

Exclusion criteria

* previous radioembolization of one or more liver lobes or segments without available treatment planning and procedural documentation ie. at another facility prior to URMC Y-90 radioembolization.

Design outcomes

Primary

Measure	Time frame	Description
Lung dose measured with actual lung mass vs Lung dose measured with conventional method.	1 month after treatment.	Lung dose measured with actual lung mass vs Lung dose measured with conventional method which assumes 1 kg for all patients. Patient will be receiving this treatment even if not enrolled on this study. The study is NOT about the intervention given to the patient. The study is to determine the best way to measure the radiation dose normal tissue (the lung specifically) receives during this standard treatment.

Countries

United States

Outcome results